Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novo Nordisk's Japan Unit To Apply For Regulatory Approval Of Stronger Insulin Drugs

This article was originally published in PharmAsia News

Executive Summary

The Japanese unit of Danish drug maker Novo Nordisk plans to apply for Japanese approval of a pair of insulin-injection products it hopes to begin marketing next year. Novo Nordisk Pharma already has NovoRapid 30 Mix on the Japanese market, but the two new versions, also rapid-acting, contain higher amounts of insulin aspart. The new variations are NovoRapid 50 Mix and NovoRapid 70 Mix, which Novo Nordisk Pharma hopes will help stave off nascent competition from other drug makers as Japan deals with rising obesity associated with diabetes. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts